Volume 13, Number 5—May 2007
Dispatch
Tuberculosis Drug Resistance and HIV Infection, the Netherlands
Catharina Hendrika Haar*†, Frank G.J. Cobelens*‡
, Nico A. Kalisvaart*, Jan J. van der Have†, Paul J.H.J. van Gerven*, and Dick van Soolingen§
, Nico A. Kalisvaart*, Jan J. van der Have†, Paul J.H.J. van Gerven*, and Dick van Soolingen§
Table 2
Prevalence of secondary drug resistance among previously treated tuberculosis patients, the Netherlands, 1993–2001*
| No. HIV negative (%)
(n = 294) |
No. HIV positive (%)
(n = 21) |
|
|---|---|---|
| Fully susceptible | 232 (78.9) | 15 (71.4) |
| Resistant to 1 drug:
Isoniazid
Rifampin
Streptomycin |
34 (11.9)
20 (6.8)
0
14 (4.8) |
4 (19.0)
2 (9.5)
2 (9.5)
0 |
| Resistant to 2 drugs |
17 (5.8) |
0 |
| Resistant to 3 drugs |
4 (1.4) |
0 |
| Resistant to 4 drugs |
7 (2.4) |
2 (9.5) |
| Any resistance |
62 (21.1) |
6 (28.6) |
| Any resistance to: |
||
| Isoniazid |
48 (16.3) |
4 (19.0) |
| Rifampin |
15 (5.1) |
4 (19.0)* |
| Streptomycin |
36 (12.2) |
2 (9.5) |
| Ethambutol |
9 (3.1) |
2 (9.5) |
| Multidrug resistance† | 15 (5.1) | 2 (9.5) |
*Undajusted odds ratio 4.12 (95% confidence interval 1.01–15.67, p = 0.036).
†Resistant to at least isoniazid and rifampin.
Page created: June 23, 2010
Page updated: June 23, 2010
Page reviewed: June 23, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.